Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Infliximab biosimilar by Xentria for Pulmonary Sarcoidosis: Likelihood of Approval
Infliximab biosimilar is under clinical development by Xentria and currently in Phase II for Pulmonary Sarcoidosis. According to GlobalData, Phase...
Data Insights
Infliximab biosimilar by Celltrion for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...